Public Employees Retirement System of Ohio Buys Shares of 321,841 Novo Nordisk A/S $NVO

Public Employees Retirement System of Ohio purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 321,841 shares of the company’s stock, valued at approximately $15,429,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. boosted its stake in Novo Nordisk A/S by 2,414.4% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 297,881 shares of the company’s stock valued at $14,280,000 after purchasing an additional 286,034 shares in the last quarter. Trust Co. of Vermont bought a new stake in shares of Novo Nordisk A/S in the 2nd quarter worth $1,250,000. Burkett Asset Management Ltd acquired a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at $1,823,000. Myriad Asset Management Advisors LLC bought a new position in Novo Nordisk A/S during the second quarter valued at about $1,846,000. Finally, Pine Valley Investments Ltd Liability Co bought a new position in Novo Nordisk A/S during the second quarter valued at about $2,324,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 0.0%

NYSE:NVO opened at $45.59 on Monday. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $64.16. The firm has a market capitalization of $203.56 billion, a price-to-earnings ratio of 11.15, a price-to-earnings-growth ratio of 4.08 and a beta of 0.76. The stock has a fifty day simple moving average of $48.03 and a 200 day simple moving average of $43.86.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%.The firm had revenue of $11.98 billion for the quarter. Sell-side analysts forecast that Novo Nordisk A/S will post 3.45 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently declared a dividend, which was paid on Tuesday, August 25th. Stockholders of record on Monday, August 17th were issued a dividend of $0.5786 per share. The ex-dividend date was Monday, August 17th. This represents a dividend yield of 258.0%. Novo Nordisk A/S’s payout ratio is currently 20.05%.

Analyst Ratings Changes

Several brokerages have commented on NVO. Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, July 20th. Wall Street Zen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Friday, June 19th. Finally, BMO Capital Markets restated a “market perform” rating and set a $47.00 target price on shares of Novo Nordisk A/S in a report on Thursday, August 6th. Four equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $64.94.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: China’s drug regulator accepted Novo Nordisk’s application for an oral version of Wegovy, an important regulatory milestone that could broaden access to its obesity treatment and support future growth in a major market. China drug regulator accepts Novo Nordisk’s application for oral Wegovy
• Positive Sentiment: Some investors view Novo Nordisk as potentially undervalued following its selloff. A report also suggests that shifting legal risks surrounding compounded or competing GLP-1 products could improve the outlook for branded treatments such as Ozempic and Wegovy. Novo Nordisk stock may be cheap as GLP-1 legal risks shift
• Neutral Sentiment: Novo Nordisk’s U.S. shares recently traded near $46, below the 50-day average but above the 200-day average. Its relatively low forward valuation may limit downside for value-oriented investors, but the stock’s price-to-earnings-growth ratio indicates that a recovery is not yet fully reflected in earnings expectations.
• Negative Sentiment: Deutsche Bank downgraded Novo Nordisk from Hold to Sell and cut its price target from 290 to 265 Danish kroner. The bank cited doubts about a return to growth, intensifying competition from Eli Lilly, a looming patent-related revenue cliff and weakness in the company’s development pipeline. Deutsche Bank cuts Novo Nordisk to Sell after earnings
• Negative Sentiment: Investor concerns were reinforced by mixed second-quarter results and the late-stage failure of cardiovascular drug candidate Ziltivekimab, which Deutsche Bank reportedly considers effectively removed from the company’s near-term growth prospects. Novo’s 2027 growth rebound faces fresh doubts

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.